Overview
Intelliseq is a company that provides a cloud-based platform for the analysis of Next-Generation Sequencing (NGS) data and clinical interpretation. Their services include automated genomic analysis and reporting through products like iFlow™ and GeneSpect™ Reporters, which cover various medical conditions such as hereditary cancers and cardiovascular diseases. The platform is designed for ease of use, allowing users to perform analyses without needing extensive expertise.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2014-09-30. Active
38 1050 1445 1000 0024 9227 3905- 35 1050 1445 1000 0090 8004 7583
- 37 1050 1445 1000 0090 3039 0919
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| May 30, 2025 | Shareholders' meeting convened | |
| Jun 3, 2024 | Shareholders' meeting convened | |
| Jun 2, 2023 | Shareholders' meeting convened |
Public aid
11 public aid cases recorded, with a total value of $3,418,000.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 4, 2022 | Aid for SME access to finance — risk finance aid | —— | PFR Ventures sp. z o.o. | |
| Nov 12, 2019 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | —— | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Aug 5, 2019 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | —— | Fundacja Instytut Studiów Wschodnich |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $1,880,474.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-10-01 | Opracowanie systemu farmakologicznej interpretacji genomu - PGx Plus | $869.3K$869,306 | Program Operacyjny Inteligentny Rozwój | |
| 2019-04-08 | Promocja produktów informatyki genetycznej marki Intelliseq na rynku amerykańskim | $79,094$79,094 | Program Operacyjny Inteligentny Rozwój | |
| 2019-01-01 | Opracowanie innowacyjnej technologii wytwarzania aplikacji mobilnych dla genetyki konsumenckiej - MOBIGEN | $420.3K$420,277 | Regionalny Program Operacyjny Województwa Małopolskiego na lata 2014-2020 |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
If the company has a one-person management board, it will be represented by one member (the President) of the management board, whereas if it has a multi-member management board, it will be represented as follows: A. by two members of the management board jointly; B. notwithstanding the foregoing provisions, if a member of the management board serving as Financial Director is appointed, the company will be represented by two members of the management board acting jointly, one of whom will be the member of the management board serving as Financial Director.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Bartosz Drabikowski (56)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). | |
Adam Żelezik (51) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Digital Pathology Team Witold Reznersp. k. | $383,078.99 | digitalpathologyteam.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| Dicellasp. z o.o. | $206,073.49 | dicella.com | ||
| Nexbiosp. z o.o. | $186,582.40 | nexbio.pl | ||
| AI Corelabsp. z o.o. | $106,857.00 | aicorelab.com | ||
| GMT GenomicsS.A. | $89,076.86 | genomtec.com | ||
| Sfpesp. z o.o. | $72,850.26 | sfpe.co.pl | ||
| Xenstatssp. z o.o. | $66,774.27 | xenstats.com | ||
| Digital Pathology Teamsp. z o.o. | $64,552.91 | digitalpathologyteam.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-11-28 | Share capital change (3,014,404.50 PLN → 3,032,404.50 PLN) | |
| 2025-09-19 | Share capital change (2,930,595.50 PLN → 3,014,404.50 PLN) | |
| 2025-05-19 | Share capital change (2,672,404.50 PLN → 2,930,595.50 PLN) | |
| 2025-02-28 | Share capital change (1,827,409.00 PLN → 2,672,404.50 PLN) | |
| 2022-12-30 | Share capital change (1,250,220.00 PLN → 1,827,409.00 PLN) |
FAQ
Last updated: 2026-10-03